

Naruto Taira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223941/publications.pdf>

Version: 2024-02-01

70
papers

940
citations

471061

17
h-index

500791

28
g-index

78
all docs

78
docs citations

78
times ranked

1507
citing authors

#	ARTICLE	IF	CITATIONS
1	Phyllodes Tumor of the Breast: Stromal Overgrowth and Histological Classification are Useful Prognosis-predictive Factors for Local Recurrence in Patients with a Positive Surgical Margin. Japanese Journal of Clinical Oncology, 2007, 37, 730-736.	0.6	84
2	Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Research and Treatment, 2011, 128, 735-747.	1.1	77
3	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Research and Treatment, 2019, 173, 123-133.	1.1	77
4	The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Research, 2010, 12, R43.	2.2	56
5	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of Clinical Oncology, 2020, 38, 3743-3752.	0.8	50
6	Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. Japanese Journal of Clinical Oncology, 2011, 41, 709-712.	0.6	38
7	Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women. BMC Cancer, 2013, 13, 565.	1.1	37
8	Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 cancer. Cancer Science, 2011, 102, 2038-2042.	1.7	36
9	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. Breast Cancer Research and Treatment, 2018, 167, 39-47.	1.1	28
10	Determination of Indication for Sentinel Lymph Node Biopsy in Clinical Node-negative Breast Cancer Using Preoperative 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging. Japanese Journal of Clinical Oncology, 2008, 39, 16-21.	0.6	27
11	Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. Journal of Clinical Pathology, 2014, 67, 748-750.	1.0	23
12	Comprehensive geriatric assessment in elderly breast cancer patients. Breast Cancer, 2010, 17, 183-189.	1.3	22
13	Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life 2 years after breast cancer surgery. Breast Cancer, 2014, 21, 183-190.	1.3	22
14	Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Research and Treatment, 2014, 145, 155-164.	1.1	21
15	Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. Pharmacoeconomics, 2018, 36, 215-223.	1.7	21
16	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. Oncotarget, 2017, 8, 26122-26128.	0.8	19
17	Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).. Journal of Clinical Oncology, 2018, 36, 510-510.	0.8	18
18	The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition. Breast Cancer, 2016, 23, 343-356.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery. <i>Breast Cancer</i> , 2017, 24, 288-298.	1.3	17
20	Association between mammographic breast density and lifestyle in Japanese women. <i>Acta Medica Okayama</i> , 2013, 67, 145-51.	0.1	17
21	Influence of breast density on breast cancer risk: a case control study in Japanese women. <i>Breast Cancer</i> , 2020, 27, 277-283.	1.3	16
22	Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 354.	1.0	16
23	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	0.8	16
24	Contrast-enhanced CT Evaluation of Clinically and Mammographically Occult Multiple Breast Tumors in Women with Unilateral Early Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 419-425.	0.6	13
25	Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan. <i>Breast Cancer</i> , 2021, 28, 1-8.	1.3	11
26	The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. <i>Breast Cancer</i> , 2015, 22, 16-27.	1.3	10
27	Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 307-316.	1.1	10
28	Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 95-100.e1.	1.1	9
29	Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. <i>Breast</i> , 2021, 55, 63-68.	0.9	9
30	Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. <i>Breast</i> , 2021, 56, 70-77.	0.9	9
31	Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection. <i>Case Reports in Gastrointestinal Medicine</i> , 2016, 2016, 1-5.	0.2	8
32	Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1070-1070.	0.8	8
33	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
34	A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 289-294.	1.1	7
35	Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. <i>European Journal of Cancer</i> , 2021, 154, 157-166.	1.3	7
36	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIIOUS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 855-859.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Response Shift—Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling. <i>Value in Health</i> , 2020, 23, 768-774.	0.1	6
38	YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12809.	1.8	6
39	A single-nucleotide polymorphism in a gene modulating glucocorticoid sensitivity is associated with the decline in total lung capacity after lung transplantation. <i>Surgery Today</i> , 2019, 49, 268-274.	0.7	5
40	Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients's Health Status in Greater Detail?. <i>Medical Decision Making</i> , 2022, 42, 60-67.	1.2	5
41	Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 675-683.	1.1	5
42	Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 636-649.	5.1	5
43	Impact of modifiable lifestyle factors on outcomes after breast cancer diagnosis: the Setouchi Breast Cancer Cohort Study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 600-2.	0.6	4
44	N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women. <i>Breast Cancer</i> , 2017, 24, 254-262.	1.3	4
45	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. <i>Breast Cancer</i> , 2020, 27, 973-981.	1.3	4
46	A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course. <i>Case Reports in Oncology</i> , 2014, 7, 840-844.	0.3	3
47	Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan. <i>Breast Cancer</i> , 2018, 25, 60-67.	1.3	3
48	The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer. <i>Breast Cancer</i> , 2018, 25, 717-722.	1.3	3
49	Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 117-124.e4.	1.1	3
50	Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. <i>Quality of Life Research</i> , 2022, 31, 1829-1836.	1.5	3
51	Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women. <i>Breast Cancer</i> , 2021, 28, 478-487.	1.3	2
52	A Multicenter Study of Docetaxel at a Dose of 100 mg/m ² in Japanese Patients with Advanced or Recurrent Breast Cancer. <i>Internal Medicine</i> , 2021, 60, 1183-1190.	0.3	2
53	Cost-Effectiveness Analysis of Bevacizumab in Combined Chemotherapy for Human epidermal growth factor receptor 2-negative Metastatic Breast Cancer in Japan. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2013, 18, 1-12.	0.0	2
54	Older patients' experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2022, 57, 102115.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2022, 29, 131-143.	1.3	1
56	Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS657-TPS657.	0.8	1
57	Safety and efficacy of gemcitabine and trastuzumab in HER2-directed therapy pretreated patients with HER2-positive metastatic breast cancer: SBP-01 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 142-142.	0.8	1
58	Desmoid-type fibromatosis of the breast mimicking cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1084-1085.	0.6	0
59	A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. <i>Clinical Breast Cancer</i> , 2021, 21, 450-457.	1.1	0
60	A CASE OF BREAST CANCER METASTASIZED TO THE CHOROIDEA OF THE LEFT EYE. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2003, 64, 1082-1085.	0.0	0
61	N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS654-TPS654.	0.8	0
62	Analysis of health-related quality of life during neoadjuvant endocrine therapy with letrozole in postmenopausal breast cancer patients: N-SAS BC06 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6588-6588.	0.8	0
63	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS636-TPS636.	0.8	0
64	Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).. <i>Journal of Clinical Oncology</i> , 2016, 34, e23274-e23274.	0.8	0
65	The influences of preoperative metformin on immunological factors in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14182-e14182.	0.8	0
66	Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT). <i>Cancer Research</i> , 2022, 82, PD13-09-PD13-09.	0.4	0
67	Abstract OT1-12-08: Randomized study comparing electronic patient reported outcomes (ePROs) monitoring with routine follow up during trastuzumab deruxtecan treatment in patients with inoperable or metastatic breast cancer (PRO-DUCE study). <i>Cancer Research</i> , 2022, 82, OT1-12-08-OT1-12-08.	0.4	0
68	Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 253-262.	1.1	0
69	Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma. <i>Acta Medica Okayama</i> , 2020, 74, 401-406.	0.1	0
70	Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer. <i>Acta Medica Okayama</i> , 2021, 75, 357-362.	0.1	0